Pharmacokinetic interaction between simvastatin and fenofibrate with staggered and simultaneous dosing: Does it matter?

Journal of Clinical Pharmacology

Volumn 54, Issue 9, 2014, Pages 1038-1047

  Winsemius, Anneke ^a   Ansquer, Jean Claude ^b   Olbrich, Matthias ^c   Van Amsterdam, Peter ^a   Aubonnet, Patrick ^d   Beckmann, Katrin ^c   Driessen, Stefan ^a   Van Assche, Hanneke ^a   Piskol, Gabi ^e   Lehnick, Dirk ^e   Mihara, Katsuhiro ^a  

^a Chemical Design and Synthesis Unit   (Netherlands)

^b Clinsciences   (France)

^c ABBOTT GMBH AND CO KG   (Germany)

^d ABBOTT LABORATORIES   (United States)

^e Nuvisan GmbH   (Germany)

Author keywords

coadministration; drug drug interaction; fenofibrate; pharmacokinetic; simvastatin

Indexed keywords

CREATINE KINASE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYOGLOBIN; SIMVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; CHOLESTEROL; ORGANIC ANION TRANSPORTER; SLCO1B1 PROTEIN, HUMAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; HUMAN; HYPERTENSION; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MYALGIA; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG INTERACTION; GENETICS;

CHOLESTEROL; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FENOFIBRATE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; SIMVASTATIN; TRIGLYCERIDES;

EID: 84905447127     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.291     Document Type: Article

References (15)

1. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Eng J Med. 2010; 362: 1563-1574.
2. Bergman AJ, Murphy G, Burke J, et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol. 2004; 44: 1054-1062.
3. EMA Guideline on bioanalytical method validation. London, 21 July 2011 EMA/CHMP/EWP/192217/2009.
4. EMA Guideline on the investigation of bioequivalence. London, 20 January 2010 CPMP/EWP/QWP/1401/98 Rev. 1/ Corr.
5. Niemi M, Pasanen MK, Neuvonen PJ,. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011; 63: 157-181.
6. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M,. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006; 16: 873-879.
7. Wilke RA, Ramsey LB, Johnson SG, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012; 92: 112-117.
8. Whitfield LR, Porcari AR, Alvey C, Abel R, Bullen W, Hartman D,. Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. J Clin Pharmacol. 2011; 51: 378-388.
9. Pan WJ, Gustavson L, Achari R, et al. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol. 2000; 40: 316-323.
10. Martin PD, Dane AL, Schneck DW, Warwick MJ,. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther. 2003; 25: 459-471.
11. Elsby R, Hilgendorf C, Kenner K,. Understanding the critical pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1. Clin Pharmacol Ther. 2012; 92: 584-598.
12. Fukami T, Takahashi S, Nakagawa N, Maruichi T, Nakajima M, Yokoi T,. In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities. Drug Metab Dispos. 2010; 38: 2173-2178.
13. Yamazaki M, Li B, Louie SW, et al. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica. 2005; 35: 737-753.
14. Kajosaari LI, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ,. Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. Br J Clin Pharmacol. 2004; 58: 390-396.
15. Li J, Volpe DA, Wang Y, et al. Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos. 2011; 39: 1196-1202.